4DMedical Ltd (AU:4DX)
ASX:4DX
Want to see AU:4DX full AI Analyst Report?
Top Page
4DMedical Ltd
(Sydney:4DX)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$3.00
â–¼(-48.63% Downside)
Action:ReiteratedDate:05/08/26
The score is primarily held down by weak financial performance—declining revenue, ongoing losses, and negative operating/free cash flow. Technicals also remain bearish (below key moving averages with negative MACD), despite oversold readings that could indicate near-term stabilization risk/reward. Valuation is difficult to support because losses drive a negative P/E and there is no dividend yield data.
Positive Factors
Proprietary XV imaging technology
4DMedical’s XV CT-based imaging and XV Lung Ventilation Analysis platform represent a differentiated, software-driven capability for functional lung mapping. This proprietary tech creates a durable competitive moat in respiratory imaging, enabling recurring clinical workflows and scalable software deployment across hospitals and lung specialists.
Negative Factors
Declining revenue growth
Sustained top-line contraction undermines the company’s ability to leverage fixed costs and scale its software platform. Declining revenue signals adoption headwinds or competitive pressure in clinical channels, which can delay breakeven, reduce market share momentum, and constrain funding for trials and sales expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary XV imaging technology
4DMedical’s XV CT-based imaging and XV Lung Ventilation Analysis platform represent a differentiated, software-driven capability for functional lung mapping. This proprietary tech creates a durable competitive moat in respiratory imaging, enabling recurring clinical workflows and scalable software deployment across hospitals and lung specialists.
Read all positive factors
4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.90B
Dividend YieldN/A
Average Volume (3M)10.77M
Price to Earnings (P/E)―
Beta (1Y)2.43
Revenue Growth-0.80%
EPS Growth-249.48%
CountryAU
Employees145
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.32
Shares Outstanding592,730,200
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.45Price Target Upside-23.80% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)AU$9.00M
4DMedical Ltd Business Overview & Revenue Model
Company Description
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung venti...
How the Company Makes Money
null...
4DMedical Ltd Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
45
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.33M | 5.85M | 3.75M | 718.58K | 1.05M | 216.98K |
| Gross Profit | -17.18M | 5.39M | 3.52M | 684.43K | 280.62K | 125.13K |
| EBITDA | -35.46M | -45.82M | -31.86M | -33.74M | -35.25M | -18.04M |
| Net Income | -159.59M | -30.07M | -35.98M | -31.46M | -24.59M | -21.42M |
Balance Sheet | ||||||
| Total Assets | 139.55M | 94.81M | 120.02M | 92.92M | 74.31M | 92.64M |
| Cash, Cash Equivalents and Short-Term Investments | 56.76M | 6.88M | 30.61M | 69.58M | 51.11M | 80.88M |
| Total Debt | 6.42M | 4.31M | 5.12M | 5.14M | 6.24M | 1.69M |
| Total Liabilities | 167.95M | 30.58M | 49.09M | 21.46M | 14.80M | 9.28M |
| Stockholders Equity | -28.40M | 64.24M | 70.93M | 71.46M | 59.51M | 83.36M |
Cash Flow | ||||||
| Free Cash Flow | -22.99M | -34.56M | -31.17M | -23.38M | -28.35M | -15.25M |
| Operating Cash Flow | -22.82M | -34.48M | -30.87M | -22.65M | -25.27M | -14.52M |
| Investing Cash Flow | -1.62M | -1.62M | -40.04M | -1.61M | -3.50M | -580.45K |
| Financing Cash Flow | 75.41M | 12.37M | 31.94M | 42.73M | -995.47K | 87.55M |
4DMedical Ltd Technical Analysis
Positive
5.84
Price Trends
4.64
Positive
3.91
Positive
2.54
Positive
Market Momentum
0.51
Positive
54.43
Neutral
32.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Positive. The current price of 5.84 is above the 20-day moving average (MA) of 5.78, above the 50-day MA of 4.64, and above the 200-day MA of 2.54, indicating a bullish trend. The MACD of 0.51 indicates Positive momentum. The RSI at 54.43 is Neutral, neither overbought nor oversold. The STOCH value of 32.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:4DX.
4DMedical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$221.38M | -47.06 | -2.00% | ― | 16.92% | 76.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$17.54M | -1.41 | -165.13% | ― | 23.30% | -14.29% | |
44 Neutral | AU$106.53M | -2.83 | -54.48% | ― | 17.24% | -20.00% | |
44 Neutral | AU$177.28M | -10.00 | -70.29% | ― | ― | -62.15% | |
41 Neutral | AU$1.90B | -3.16 | -890.76% | ― | -0.80% | -249.48% | |
41 Neutral | AU$39.38M | -2.66 | -180.06% | ― | 74.74% | 4.32% |
* Healthcare Sector Average
AU:4DX
4DMedical Ltd
3.21
2.92
1006.90%
AU:IPD
Impedimed Limited
0.01
-0.02
-58.82%
AU:CYC
Cyclopharm Limited
0.85
-0.38
-30.74%
AU:MX1
Micro-X Ltd.
0.05
>-0.01
-10.00%
AU:ARX
Aroa Biosurgery Ltd
0.64
0.20
45.45%
AU:EMV
EMvision Medical Devices Ltd.
1.91
0.07
3.64%
4DMedical Ltd Corporate Events
State Street Group Ceases to Be Substantial Holder in 4DMedical
May 4, 2026
State Street Corporation and several of its asset management subsidiaries, including State Street Global Advisors entities in Australia, Europe and the U.S., have disclosed that they have ceased to be substantial shareholders in 4DMedical Ltd. The...
4DMedical Seeks ASX Quotation for 2.16 Million New Shares
May 1, 2026
4DMedical Ltd has applied to the ASX for quotation of new ordinary fully paid shares following the conversion of options or other convertible securities. The application covers a total of 2,159,719 shares issued across three dates in April and May...
4DMedical accelerates global rollout of CT:VQ on surging scan volumes and fresh capital
Apr 30, 2026
4DMedical reported strong third-quarter momentum as it deepens penetration of leading U.S. academic medical centres with its CT:VQ lung imaging platform, adding a commercial contract with University of Chicago Medicine and a 90-day evaluation at M...
4DMedical Issues New Shares Under Long-Term Incentive Plan, Confirms Regulatory Compliance
Apr 17, 2026
4DMedical Limited has issued 162,045 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan, expanding its share capital without a formal prospectus disclosure. The company confirmed it is compliant with ke...
4DMedical Seeks ASX Quotation for Additional 1.2 Million Shares
Apr 17, 2026
4DMedical Limited has applied to the ASX for quotation of an additional 1,206,912 ordinary fully paid shares, issued on 10 April and 17 April 2026, under its ticker 4DX. The new securities arise from the exercise or conversion of existing options ...
4DMedical to Join S&P/ASX 200 as Insignia Financial Exits
Apr 13, 2026
SP Dow Jones Indices will remove Insignia Financial Limited from the SP/ASX 200 Index following its proposed acquisition by Daintree BidCo Pty Ltd, with the change scheduled to take effect before trading opens on 20 April 2026. 4DMedical Limited w...
4DMedical Seeks ASX Quotation for 938,175 Newly Issued Shares
Apr 2, 2026
4DMedical Ltd has applied for quotation on the ASX of a total of 938,175 new fully paid ordinary shares, issued in two tranches on 27 March 2026 and 2 April 2026. The additional shares, arising from the exercise or conversion of existing options o...
4DMedical Issues Over 14 Million New Shares and Confirms Regulatory Compliance
Apr 1, 2026
4DMedical has issued 14,067,797 fully paid ordinary shares, in line with prior announcements, and confirmed that the shares were issued without the need for a disclosure document under the Corporations Act. The company stated it remains compliant ...
4DMedical Seeks ASX Quotation for 14 Million New Shares
Apr 1, 2026
4DMedical Ltd has applied for quotation on the ASX of 14,067,797 new ordinary fully paid shares, with an issue date of 2 April 2026. The additional securities, previously flagged in an Appendix 3B, will increase the company’s free float and ...
4DMedical plans new share issue to fund growth
Mar 26, 2026
4DMedical Ltd, an ASX-listed medtech company specialising in lung imaging and respiratory diagnostic technologies, continues to build its capital base to support its commercial and development activities. The company operates under the ticker 4DX ...
4DMedical wins EU approval for CT:VQ and raises $83m to drive expansion
Mar 26, 2026
4DMedical has secured CE Mark certification for its CT:VQ™ ventilation-perfusion imaging technology, clearing the way for commercial deployment across the European Union, one of the world’s largest markets for cardiothoracic imaging. T...
4DMedical wins Mayo Clinic deployment in push to make CT:VQ lung imaging standard of care
Mar 24, 2026
4DMedical has secured deployment of its CT:VQ ventilation-perfusion imaging technology at Mayo Clinic, the top-ranked U.S. hospital, marking a major endorsement of its platform by one of the most influential healthcare institutions globally. The i...
4DMedical Issues New Shares Under Incentive Plan and Confirms Regulatory Compliance
Mar 18, 2026
4DMedical has issued 485,976 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan, expanding its share base in line with previously established employee and executive remuneration structures. The company ...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Mar 18, 2026
4DMedical has applied for quotation on the ASX of 485,976 new fully paid ordinary shares, to be issued on 18 March 2026 under the ticker 4DX. The move modestly increases the company’s listed share capital and reflects the conversion of exist...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Mar 13, 2026
4DMedical Ltd has applied to the ASX for quotation of an additional 87,546 ordinary fully paid shares, issued in two tranches on March 6 and March 13, 2026. The new securities stem from the exercise or conversion of existing options or other conve...
4DMedical Added to All Ordinaries in S&P Dow Jones March Rebalance
Mar 10, 2026
4DMedical Limited has been added to the SP/ASX All Ordinaries Index as part of SP Dow Jones Indices’ March 2026 quarterly rebalance, effective before the market opens on 23 March 2026. The reshuffle reverses earlier plans affecting African G...
4DMedical Joins S&P/ASX 300 in Broad Rebalance of Australian Indices
Mar 6, 2026
SP Dow Jones Indices has announced its March 2026 quarterly rebalance of the SP/ASX suite, shifting membership across the 20, 50, 100, 200, and 300 benchmarks effective before trading on March 23. The reshuffle reflects evolving market capitalisat...
4DMedical directors boost equity stakes as respiratory imaging portfolio expands
Mar 4, 2026
4DMedical Limited, a global medtech company specialising in AI-enhanced respiratory imaging, develops and commercialises software solutions such as XV Lung Ventilation Analysis Software, CT LVAS and CT:VQ, all delivered through a SaaS model for se...
4DMedical Issues New Shares Under Long-Term Incentive Plan, Confirms Regulatory Compliance
Mar 4, 2026
4DMedical has issued 1,583,776 fully paid ordinary shares following the exercise of options and restricted stock units under its Long Term Incentive Plan, with the issuance recorded in an Appendix 2A lodged with the ASX. The company has confirmed ...
4DMedical Seeks ASX Quotation for 1.58 Million New Shares
Mar 4, 2026
4DMedical Ltd has applied for quotation on the ASX of 1,583,776 new fully paid ordinary shares issued on 26 February 2026, following the exercise or conversion of existing options or other convertible securities. The additional shares will increas...
4DMedical Seeks ASX Quotation for Additional Ordinary Shares
Feb 27, 2026
4DMedical Ltd has applied to the ASX for quotation of 9,070 new fully paid ordinary shares under its ticker 4DX. The securities, issued on 23 February 2026 following the exercise or conversion of existing instruments, represent a minor increase to...
4DMedical Seeks ASX Quotation for 2 Million New Shares
Feb 20, 2026
4DMedical has applied to the ASX for quotation of 2,000,000 additional ordinary fully paid shares, issued on 13 February 2026 following the exercise of options or conversion of other securities. The move modestly increases the company’s free...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.